These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 29677353)

  • 1. Humoral Immune Response After Intravitreal But Not After Subretinal AAV8 in Primates and Patients.
    Reichel FF; Peters T; Wilhelm B; Biel M; Ueffing M; Wissinger B; Bartz-Schmidt KU; Klein R; Michalakis S; Fischer MD;
    Invest Ophthalmol Vis Sci; 2018 Apr; 59(5):1910-1915. PubMed ID: 29677353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superior Retinal Gene Transfer and Biodistribution Profile of Subretinal Versus Intravitreal Delivery of AAV8 in Nonhuman Primates.
    Seitz IP; Michalakis S; Wilhelm B; Reichel FF; Ochakovski GA; Zrenner E; Ueffing M; Biel M; Wissinger B; Bartz-Schmidt KU; Peters T; Fischer MD;
    Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5792-5801. PubMed ID: 29117317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Toxicology of Ocular Gene Therapy with Recombinant AAV Vector rAAV.hCNGA3 in Nonhuman Primates.
    Tobias P; Philipp SI; Stylianos M; Martin B; Barbara W; Felix R; Alexander OG; Eberhart Z; Marius U; Birgit K; Sven K; Ulrich BK; Dominik FM;
    Hum Gene Ther Clin Dev; 2019 Jun; 30(2):50-56. PubMed ID: 30864850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Biodistribution Evaluation in CNGB3-Deficient Mice of rAAV2tYF-PR1.7-hCNGB3, a Recombinant AAV Vector for Treatment of Achromatopsia.
    Ye GJ; Budzynski E; Sonnentag P; Nork TM; Miller PE; McPherson L; Ver Hoeve JN; Smith LM; Arndt T; Mandapati S; Robinson PM; Calcedo R; Knop DR; Hauswirth WW; Chulay JD
    Hum Gene Ther Clin Dev; 2016 Mar; 27(1):27-36. PubMed ID: 27003752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-PR1.7-hCNGB3, a Recombinant AAV Vector for Treatment of Achromatopsia.
    Ye GJ; Budzynski E; Sonnentag P; Nork TM; Miller PE; Sharma AK; Ver Hoeve JN; Smith LM; Arndt T; Calcedo R; Gaskin C; Robinson PM; Knop DR; Hauswirth WW; Chulay JD
    Hum Gene Ther Clin Dev; 2016 Mar; 27(1):37-48. PubMed ID: 27003753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates.
    Kotterman MA; Yin L; Strazzeri JM; Flannery JG; Merigan WH; Schaffer DV
    Gene Ther; 2015 Feb; 22(2):116-26. PubMed ID: 25503696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal Evaluation of Hyper-Reflective Foci in the Retina Following Subretinal Delivery of Adeno-Associated Virus in Non-Human Primates.
    Rodríguez-Bocanegra E; Wozar F; Seitz IP; Reichel FFL; Ochakovski A; Bucher K; Wilhelm B; Bartz-Schmidt KU; Peters T; Fischer MD;
    Transl Vis Sci Technol; 2021 May; 10(6):15. PubMed ID: 34111260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy Evaluation of rAAV2tYF-PR1.7-hCNGA3 Vector Delivered by Subretinal Injection in CNGA3 Mutant Achromatopsia Sheep.
    Gootwine E; Ofri R; Banin E; Obolensky A; Averbukh E; Ezra-Elia R; Ross M; Honig H; Rosov A; Yamin E; Ye GJ; Knop DR; Robinson PM; Chulay JD; Shearman MS
    Hum Gene Ther Clin Dev; 2017 Jun; 28(2):96-107. PubMed ID: 28478700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical safety evaluation of a recombinant AAV8 vector for X-linked retinoschisis after intravitreal administration in rabbits.
    Marangoni D; Wu Z; Wiley HE; Zeiss CJ; Vijayasarathy C; Zeng Y; Hiriyanna S; Bush RA; Wei LL; Colosi P; Sieving PA
    Hum Gene Ther Clin Dev; 2014 Dec; 25(4):202-11. PubMed ID: 25211193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additional transduction events after subretinal readministration of recombinant adeno-associated virus.
    Anand V; Chirmule N; Fersh M; Maguire AM; Bennett J
    Hum Gene Ther; 2000 Feb; 11(3):449-57. PubMed ID: 10697119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential.
    Li Q; Miller R; Han PY; Pang J; Dinculescu A; Chiodo V; Hauswirth WW
    Mol Vis; 2008 Sep; 14():1760-9. PubMed ID: 18836574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AAV8 Can Induce Innate and Adaptive Immune Response in the Primate Eye.
    Reichel FF; Dauletbekov DL; Klein R; Peters T; Ochakovski GA; Seitz IP; Wilhelm B; Ueffing M; Biel M; Wissinger B; Michalakis S; Bartz-Schmidt KU; Fischer MD;
    Mol Ther; 2017 Dec; 25(12):2648-2660. PubMed ID: 28970046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-CB-hRS1, a Recombinant Adeno-Associated Virus Vector Expressing Retinoschisin.
    Ye GJ; Budzynski E; Sonnentag P; Miller PE; Sharma AK; Ver Hoeve JN; Howard K; Knop DR; Neuringer M; McGill T; Stoddard J; Chulay JD
    Hum Gene Ther Clin Dev; 2015 Sep; 26(3):165-76. PubMed ID: 26390090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Response and Intraocular Inflammation in Patients With Leber Hereditary Optic Neuropathy Treated With Intravitreal Injection of Recombinant Adeno-Associated Virus 2 Carrying the ND4 Gene: A Secondary Analysis of a Phase 1/2 Clinical Trial.
    Bouquet C; Vignal Clermont C; Galy A; Fitoussi S; Blouin L; Munk MR; Valero S; Meunier S; Katz B; Sahel JA; Thomasson N
    JAMA Ophthalmol; 2019 Apr; 137(4):399-406. PubMed ID: 30730541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of Photoreceptor Targeting via Intravitreal Delivery in Mouse and Human Retina Using Combinatory rAAV2 Capsid Mutant Vectors.
    Reid CA; Ertel KJ; Lipinski DM
    Invest Ophthalmol Vis Sci; 2017 Dec; 58(14):6429-6439. PubMed ID: 29260200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial.
    Ghazi NG; Abboud EB; Nowilaty SR; Alkuraya H; Alhommadi A; Cai H; Hou R; Deng WT; Boye SL; Almaghamsi A; Al Saikhan F; Al-Dhibi H; Birch D; Chung C; Colak D; LaVail MM; Vollrath D; Erger K; Wang W; Conlon T; Zhang K; Hauswirth W; Alkuraya FS
    Hum Genet; 2016 Mar; 135(3):327-43. PubMed ID: 26825853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Methodology and Study Protocol: Safety and Efficacy of a Single Subretinal Injection of rAAV.hCNGA3 in Patients with CNGA3-Linked Achromatopsia Investigated in an Exploratory Dose-Escalation Trial.
    Kahle NA; Peters T; Zobor D; Kuehlewein L; Kohl S; Zhour A; Werner A; Seitz IP; Sothilingam V; Michalakis S; Biel M; Ueffing M; Zrenner E; Bartz-Schmidt KU; Fischer MD; Wilhelm BJC
    Hum Gene Ther Clin Dev; 2018 Sep; 29(3):121-131. PubMed ID: 30187779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outer retinal transduction by AAV2-7m8 following intravitreal injection in a sheep model of CNGA3 achromatopsia.
    Ross M; Obolensky A; Averbukh E; Desrosiers M; Ezra-Elia R; Honig H; Yamin E; Rosov A; Dvir H; Gootwine E; Banin E; Dalkara D; Ofri R
    Gene Ther; 2022 Nov; 29(10-11):624-635. PubMed ID: 34853444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term retinal cone rescue using a capsid mutant AAV8 vector in a mouse model of CNGA3-achromatopsia.
    Dai X; He Y; Zhang H; Zhang Y; Liu Y; Wang M; Chen H; Pang JJ
    PLoS One; 2017; 12(11):e0188032. PubMed ID: 29131863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Dose-Escalation Study of Intravitreal AAV-RS1 Gene Therapy in a Mouse Model of X-linked Retinoschisis: Dose-Dependent Expression and Improved Retinal Structure and Function.
    Bush RA; Zeng Y; Colosi P; Kjellstrom S; Hiriyanna S; Vijayasarathy C; Santos M; Li J; Wu Z; Sieving PA
    Hum Gene Ther; 2016 May; 27(5):376-89. PubMed ID: 27036983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.